Researchers show how specific immune cells are activated by the vaccine -- an important starting point for the development of new vaccines.

Immunosuppression appears to reduce mortality among people with systemic sclerosis with pulmonary arterial hypertension but ...

A panelist discusses how axatilimab, a humanized IgG4 monoclonal antibody targeting CSF-1 receptors on monocytes and macrophages, showed promising results in the AGAVE-201 trial for ...

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic ...

Researchers show how specific immune cells are activated by the vaccine - an important starting point for the development of ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function ...

The European Commission (EC) has approved a Marketing Authorization (MA) for Tremfya (guselkumab) to treat adults with ...

Infants hospitalized with severe COVID-19 have significantly different immune responses than adults or older children. The ...

IL-23 is a cytokine secreted by activated monocyte/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases including UC. 3,4,5,6,7 a. Clinical remission was ...